Atul Varadhachary of Fannin joins the Houston Innovators Podcast. Photo via LinkedIn

Commercializing a life science innovation that has the potential to enhance or even save the lives of millions of patients is a marathon, not a sprint. That's how Atul Varadhachary thinks of it, and he's leading an organization that's actively running that race for several different early-stage innovations.

For over a decade, Fannin has worked diligently to develop promising life science innovations — that start as just an idea or research subject — by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The model is different from what you'd see at an accelerator or incubator, and it also varies from the path taken by an academic or research institution.

The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary, managing director at Fannin, says on the Houston Innovators Podcast.



Fannin addresses what Varadhachary calls a twin bottleneck in Houston's life science innovation ecosystem. Not only does Houston not attract the funding biotech startups need desperately to grow their companies, but hiring is a major issue as the city isn't home to an established labor pool of experienced product developers within the industry.

"The challenge is that product development is more complex — it requires innovation, but that's not sufficient. When you ask people why we lag in the product development in the life sciences — although we are home to the largest medical center in the country, we don't even make list of top 10 biotech clusters — the usual answer is that we don't have enough biotech investors," Varadhachary says.

"But that puts the cart before the horse," he continues. "Investors invest in people not just ideas. Although we have an amazing pool of researchers and clinicians, we lack experienced product developers."

In more ways than one, Fannin is addressing this problem. For all of its several ongoing programs, Fannin acts as the leadership team for the technologies. Its core employees — there are about 20 currently — work on all of the companies, which are developing a range life science innovations, from Brevitest, a point-of-use immunoassay platform, to Procyrion, an intra-aortic pump for congestive heart failure patients.

Fannin's programs also range in stage, which Varadhachary outlines on the show to be three different phases. The earliest stage programs will have Fannin's team working directly on early testing, product development, and grant writing, while the later stage programs will have built out a dedicated team and raise venture investment.

Another way Fannin is addressing Houston's lack of life science product developers is through its Fannin Talent Development Program, which has given around 350 individuals an opportunity to gain critical product development experience.

With 10 years under its belt, Fannin — as well as the greater Houston life science innovation ecosystem — is at a point where it can soon produce exits needed to firm up Houston as a life science leader.

"Clearly, we've got the base elements required to be a successful ecosystem, and they continue to grow," Varadhachary says of Houston. "Typically you need one or two really big success stories — especially if those success stories result in a company being sold, leaving behind experienced product developers with money in their pockets — that's often what will supercharge the next cycle of development. I'm hoping that will happen in Houston in the next five years, decade, or so."

Money moves, big deals, and more lead this roundup of innovation news. Pexels

Houston biomedical startup granted $1.5M, Chevron taps into Plug and Play, and more innovation news

Short stories

Hitting headlines this month are innovation news stories from battling the opioid crisis and funding to TMCx companies and Houston as a whole earning recognition.

In this innovation news roundup, two Houston startups pocket some cash, Chevron links up with Plug and Play, and more.

BreviTest receives grant to combat opioid crisis

BreviTest Technologies

Houston-based BreviTest can rapidly and accurately test for opioid use. Photo via brevitest.com

National Institute on Drug Abuse of the National Institutes of Health — through a Small Business Innovation Research Phase II grant — has granted $1.5 million to Houston-based BreviTest Technologies to take its opioid testing technology to the next level. With 47,600 opioid overdose deaths reported in 2017 in the United States, the startup's analyzer has a lot of potential to aid in the crisis.

"Because of the delay in receiving laboratory results, many physicians use urine drug testing sparingly. The BreviTest analyzer will allow any doctor to measure opioid urine levels in-office, which will help them identify individuals who are misusing the drugs," says BreviTest's Michael J. Heffernan, Ph.D., principal investigator on the project, in a news release.

BreviTest is a Fannin Innovation Studio company. The early-stage biomedical commercialization firm that's based in Houston is proud to see the startup's success and the difference the technology is making.

"Our BreviTest team is excited to receive this support from NIDA to advance our point-of-care diagnostics technology into the clinic," said Fannin executive chairman, Leo Linbeck III, in the release. "Putting a convenient, accurate opioid test in the hands of physicians will be an important step in combating the opioid overdose epidemic facing our country."

Houston's Plug and Play operation names Chevron as founding partner

Chevron has linked up with Plug and Play in Houston. Courtesy of CTV

Plug and Play Tech Center, which just announced the participating companies in its inaugural energy and sustainability cohort in Houston, has named Chevron as a founding partner.

"We are incredibly excited to announce Chevron as a Founding Partner of Plug and Play in Houston," says Wade Bitaraf, founder of Plug and Play's Energy & Sustainability program, in a news release. "Their commitment to invest in digital transformation and reduce the environmental impact of the industry is directly aligned with our Energy & Sustainability program in Houston, Silicon Valley, and around the world."

Barbara Burger, president of Chevron Technology Ventures, the company's venture and innovation arm, is responsible for identifying pathways to innovation for the company.

"Chevron is a proud supporter of the Houston innovation community, and our support of Plug and Play's Energy & Sustainability platform demonstrates our commitment to growing the Houston innovation ecosystem," Burger says in the release. "Innovation will play a critical role in the future of energy, and our partnership with Plug and Play reinforces our commitment to invest in breakthrough technologies to enable the ongoing energy transition."

Houston recognized as a top 10 city for female founder success

According to Inc. 5000, Houston's great for female founders. Getty Images

Texas cities are great for fostering female founder success, according to a new ranking from Inc. 5000. Houston ranked at No. 10 of the top 10 list that factored in the women-led businesses among the magazine's 5,000 fastest-growing private U.S. companies.

"The Houston metropolitan area is home to 15 women-owned Inc. 5000 companies, including online marketing startup Decode Digital Marketing (No. 973) and health care staffing firm Restore Rehab Services (No. 2,645)," reads the ranking. "Together the 15 firms grew their collective revenue 142 percent between 2015 and 2018."

Dallas and Austin both appeared on the ranking, at No. 4 and No. 6, respectively.

Alice closes series A of funding

Alice founders, Elizabeth Gore (left) and Carolyn Rodz, closed their series A of funding. Getty Images

Though the company did not disclose an amount raised, Alice, an artificial intelligence-powered platform for business advice, closed a series A funding round led by SVB Financial Group, the parent company to Silicon Valley Bank.

Per a news release, the company will use the funding to "build its predictive technology, using data analytics to guide each entrepreneur through every stage of their business."

Alice, which has operations in Houston and San Francisco, reached a deal with Austin-based Bumble for funding earlier this year.

TMCx companies win big

TMCx

Three TMCx alumni companies earned some recognition at the UCSF Digital Health Awards last month. Courtesy of TMCx

Three health tech companies coming out of the Texas Medical Center's accelerator program have won big at the UCSF Digital Health Awards last month.

  • Sana Health, member of TMCx07 in 2018, won in the best behavioral health digital therapeutic category for its light-based neuromodulation pain treatment technology.
  • Meru Health, member of TMCx08 in 2019, won in the best mental health digital health therapeutic category for its mental health platform.
  • Luma Health, member of TMCx08 in 2019, won in the best EHR-integrated platform for patient engagement category for its patient communication technology.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”